Sign in

Research summary ·

A systematic review of neuroprotective therapies for visual acuity preservation in retinitis pigmentosa.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This review checked therapies that protect nerve cells in retinitis pigmentosa. The main outcome was visual acuity. Others were retina signals and side effects. Only randomized trials in typical retinitis pigmentosa were used. Searches had no date limits, and results were told in words. In all, 10 trials with 1364 people were included.

What they found

Treatments included antioxidants, GABA modulators, nerve stimulation and omega-3 fatty acids. No treatment gave a clear gain in visual acuity against control. Lycium barbarum was linked with a modest gain in a single mid-stage trial. Certainty for it was very low. Vitamin A, DHA and lutein were linked with changes in retina signals in late-stage trials. These came from secondary analyses.

What it means for patients

The authors say current evidence does not support these therapies to keep visual acuity. Some were linked with changes in secondary measures. They say larger, standardized trials are needed.

Why it is not certain yet

Samples were small. Methods differed across trials. Overall certainty was moderate to very low. The retina signal findings came from secondary analyses.

Source

A systematic review of neuroprotective therapies for visual acuity preservation in retinitis pigmentosa.

PubMed · PMID 42297463

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Retinitis pigmentosa publications